Sheng Yang

机构：Fujian Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing University of Information Science and Technology, Peking Union Medical College Hospital, Education Department of Fujian Province, Fujian Provincial Cancer Hospital, Fu Wai Hospital · ORCID：0000-0003-1630-8037

发表论文 158 篇 · 总被引 1384 次 · h-index 21

代表论文

• Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study (2025 · The Lancet Respiratory Medicine · 被引 16)
• Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients (2024 · Cancer Immunology Immunotherapy · 被引 12)
• Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed/refractory diffuse large B-cell lymphoma (2024 · Cancer Immunology Immunotherapy · 被引 8)
• Single-cell sequencing and spatial transcriptomics reveal FAS+ T cell and autophagy-related signatures predicting chemoimmunotherapy response in diffuse large B-cell lymphoma patients (2025 · Science China Life Sciences · 被引 7)
• Multiomics and Single-Cell Insights Reveal a Lysophosphatidic Acid–Mediated Resistant Mechanism to Third-generation EGFR-TKI in Non–Small Cell Lung Cancer (2025 · Clinical Cancer Research · 被引 6)
• Role and mechanism of NCAPD3 in promoting malignant behaviors in gastric cancer (2024 · Frontiers in Pharmacology · 被引 6)